Fulgent Genetics Partners with the VA to Enhance Veteran Care
Fulgent Genetics, Inc. (NASDAQ: FLGT), a pioneering provider of genetic testing services, recently secured a significant contract with the U.S. Department of Veterans Affairs (VA). This five-year agreement will allow Fulgent to deliver comprehensive hereditary cancer and pharmacogenetic testing services tailored for veterans. Through this partnership, the company aims to provide enhanced testing options that improve cancer treatment and the overall healthcare experience for veterans and their families.
Expanding Genetic Testing for Veterans
Since 2017, Fulgent has been actively involved in providing genetic testing services to VA members. With this new contract, the company is not only able to strengthen its longstanding relationship with the VA but also expand the range of services offered. This initiative is crucial for veterans with a personal or family history of cancer, allowing for better-informed treatment decisions based on genetic predispositions.
Understanding Cancer Through Genetic Insights
The new contract includes services such as hereditary cancer testing that helps identify genetic factors contributing to cancer risk. By integrating such testing into patient care, Fulgent enables healthcare providers to create personalized treatment plans that consider the unique genetic makeup of their patients. This move is a step forward in the realm of tailored medicine, where treatment protocols can be optimized based on individual genetic profiles.
The Role of Pharmacogenetic Testing
An exciting component of this partnership is the inclusion of pharmacogenetic testing, which studies how an individual’s genes can affect their response to medications. This knowledge is fundamental in delivering personalized healthcare, ensuring that veterans receive medications that align with their genetic makeup, potentially improving efficacy and reducing adverse effects. As Dr. Harry Gao, Fulgent’s Chief Scientific Officer, points out, personalized medicine facilitates better results by employing advanced genomic insights.
Fulgent’s Commitment to Quality and Innovation
Fulgent Genetics prides itself on its strong focus on quality and turnaround times, which have established it as a trustworthy partner for healthcare providers. Brandon Perthuis, the Chief Commercial Officer, expressed pride in serving veterans. He noted that understanding the genetic factors involved in cancer treatment can dramatically improve patient outcomes.
Financials of the Contract
The agreement with the VA holds the potential for financial success, valued at up to $99 million over the five-year term. This funding will support the provision of both hereditary cancer and pharmacogenetic testing services. Such a robust investment signifies the commitment from the VA to leverage cutting-edge technologies in improving patient care for veterans.
About Fulgent Genetics
Fulgent Genetics is not only focused on laboratory services but is also actively engaging in therapeutic developments aimed at revolutionizing cancer treatment. The company integrates technology and medicine, focusing on developing novel drug candidates. This commitment to healthcare innovation positions Fulgent as a key player in the move towards precision medicine.
Frequently Asked Questions
What is the main focus of the contract with the VA?
The contract focuses on providing hereditary cancer testing and pharmacogenetic testing to veterans, enhancing their healthcare experience.
How long is the contract with the VA?
The contract spans five years, allowing Fulgent to implement and provide comprehensive services throughout this period.
What are the benefits of pharmacogenetic testing?
Pharmacogenetic testing helps healthcare providers understand how veterans may respond to medications, allowing for personalized treatment plans based on genetic factors.
When did Fulgent start working with the VA?
Fulgent has been providing genetic testing services to the VA since 2017, prior to this recent contract award.
What is Fulgent’s approach to patient care?
Fulgent emphasizes quality testing and rapid turnaround times, ensuring that healthcare providers can make timely decisions based on accurate genetic information.
